false
0001979005
0001979005
2026-11-14
2026-11-14
0001979005
AFJK:OrdinarySharesParValue0.0001PerShareMember
2026-11-14
2026-11-14
0001979005
AFJK:RightsExchangeableIntoOnefifthOfOneOrdinaryShareMember
2026-11-14
2026-11-14
0001979005
AFJK:UnitsEachConsistingOfOneOrdinaryShareAndOneRightMember
2026-11-14
2026-11-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
United
States
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
November
14, 2026
Date
of Report (Date of earliest event reported)
AIMEI
HEALTH TECHNOLOGY CO., LTD
(Exact
Name of Registrant as Specified in its Charter)
| Cayman
Islands |
|
001-41880 |
|
N/A 00-0000000 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
10
East 53rd Street, Suite 3001
New
York, NY |
|
10022 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
86-13758131392
Registrant’s
telephone number, including area code
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each Class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Ordinary
Shares, par value $0.0001 per share |
|
AFJK |
|
The
Nasdaq Stock Market LLC |
| Rights,
exchangeable into one-fifth of one Ordinary Share |
|
AFJKR |
|
The
Nasdaq Stock Market LLC |
| Units,
each consisting of one Ordinary Share and one Right |
|
AFJKU |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
7.01. Regulation FD Disclosure.
On
November 14, 2026, Aimei Health Technology Co., Ltd (the “Company”) entered into a non-binding letter of intent (the
“LOI”) for a business combination (the “Proposed Transaction”) with Hera Health Solutions Inc.,
a Tennessee biotechnology and medical device company (“Hera”).
Under
the terms of the LOI, the Company and Hera would become a combined entity, with the Company acquiring 100% of Hera’s outstanding
equity and equity equivalents in exchange for shares of the combined public company. The Company expects to announce additional details
regarding the Proposed Transaction upon the execution of a definitive business combination agreement.
The
LOI is non-binding with respect to the Proposed Transaction, except for certain provisions, including those relating to confidentiality,
exclusivity, and other customary matters. The Proposed Transaction remains subject to the negotiation and execution of definitive agreements,
completion of due diligence, receipt of required regulatory and shareholder approvals, and satisfaction of other customary closing conditions.
There can be no assurance that any definitive agreement will be executed or that the Proposed Transaction will be consummated.
About
Aimei Health Technology Co., Ltd
Aimei
Health Technology Co., Ltd (Nasdaq: AFJK) is a blank check company organized as a Cayman Islands exempted company for the purpose of
effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one
or more businesses or entities.
About
Hera Health Solutions Inc.
Hera
Health Solutions Inc., a Delaware corporation headquartered in Memphis, Tennessee, is a pharmaceutical technology company developing
next-generation drug delivery solutions through its proprietary biodegradable nanofiber scaffold technology, advanced electrospinning
manufacturing platform, and AI-driven formulation capabilities. The company’s technology enables existing medicines to be reformulated
into long-acting implants, patches, and other delivery formats designed to provide sustained, controlled release over extended periods.
Complementing this manufacturing platform, Hera’s Hercules™ AI technology is designed to accelerate formulation development
and optimize drug release performance across diverse therapeutic areas, including women’s health, infectious diseases, pain management,
and metabolic disorders. Through pharmaceutical licensing and development partnerships, Hera is advancing a scalable technology platform
designed to improve treatment delivery, reduce dosing frequency, and unlock new commercial opportunities for existing therapeutics.
Additional
Information and Where to Find It
If
a legally binding definitive agreement with respect to the Proposed Transaction is executed, the Company or a holding company to be formed
in connection with the Proposed Transaction intends to file with the U.S. Securities and Exchange Commission (the “SEC”)
a registration statement on Form F-4 or Form S-4, which will include a preliminary proxy statement/prospectus (a “Proxy Statement/Prospectus”).
A definitive Proxy Statement/Prospectus will be mailed to the Company’s shareholders as of a record date to be established for
voting on the Proposed Transaction. Shareholders will also be able to obtain copies of the Proxy Statement/Prospectus, without charge,
at the SEC’s website at www.sec.gov or by directing a request to: Aimei Health Technology Co., Ltd, 10 East 53rd Street, Suite
3001, New York, NY 10022.
This
report may be deemed to be offering or solicitation material in respect of the Proposed Transaction, which will be submitted to the shareholders
of the Company for their consideration. The Company urges investors, shareholders and other interested persons to carefully read, when
available, the preliminary and definitive Proxy Statement/Prospectus as well as other documents filed with the SEC (including any amendments
or supplements to the Proxy Statement/Prospectus, as applicable), in each case, before making any investment or voting decision with
respect to the Proposed Transaction, because these documents will contain important information about the Company, Hera and the Proposed
Transaction.
Participants
in the Solicitation
The
Company and its directors and executive officers may be considered participants in the solicitation of proxies with respect to the Proposed
Transaction described herein under the rules of the SEC. Information about the directors and executive officers of the Company and a
description of their interests in the Company and the Proposed Transaction are set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on May 4, 2026 (the “Annual Report”) and the
Proxy Statement/Prospectus, when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated
above.
No
Offer or Solicitation
This
report shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of any
business combination. This report shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall
there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means
of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.
Forward-Looking
Statements
Certain
statements made in this report are “forward looking statements”. When used in this report, the words “estimates,”
“projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,”
“believes,” “seeks,” “may,” “will,” “should,” “future,” “propose”
and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify
forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve
a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s
control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important
factors, among others, that may affect actual results or outcomes include: the inability of the Company to enter into a definitive agreement
with respect to an initial business combination with Hera or any other party within the time provided in the Company’s amended
and restated memorandum and articles of association, as amended; the risk that the LOI may be terminated or that the Company and Hera
may be unable to agree on the terms of a definitive agreement; the Company’s ability to obtain shareholder approval to further
extend the date by which it must consummate an initial business combination; the Company’s ability to maintain the listing of its
securities on The Nasdaq Stock Market LLC; performance of Hera’s business; the risk that the approval of the shareholders of the
Company for the Proposed Transaction is not obtained; failure to realize the anticipated benefits of the Proposed Transaction, including
as a result of a delay in consummating the Proposed Transaction; the amount of redemption requests made by the Company’s shareholders
and the amount of funds remaining in the Company’s trust account after satisfaction of such requests; the Company’s and Hera’s
ability to satisfy the conditions to closing the Proposed Transaction; and those factors discussed in the Annual Report under the heading
“Risk Factors,” and other documents of the Company filed, or to be filed, with the SEC. The Company does not undertake any
obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except
as required by law.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
November 17, 2026
| |
Aimei
Health Technology Co., Ltd |
| |
|
|
| |
By: |
/s/
Junheng Xie |
| |
Name:
|
Junheng
Xie |
| |
Title: |
Chief
Executive Officer and Director |
| |
|
(Principal
Executive Officer) |